Treating a Specific Lymphoma with Modified T Cells

This patent describes a method to treat a difficult-to-treat type of lymphoma by taking a patient's own immune cells, modifying them to recognize and attack cancer, and then giving them back to the patient.

What it covers

This patent outlines a method for treating relapsed or refractory mantle cell lymphoma (MCL) in patients who have specific tumor characteristics, either a Ki-67 tumor proliferation index of 50% or higher, or a TP53 gene mutation (Claim 1). The treatment involves collecting a patient's own (autologous) T cells from their blood, enriching them for specific types (CD4+ and CD8+), and removing any circulating cancer cells (Claim 1). These T cells are then engineered to express a "chimeric antigen receptor" (CAR) that specifically targets a protein called CD19, using a particular anti-CD19 component called FMC63 (Claim 1). Before receiving these modified T cells, patients may get a "bridging therapy" and a "lymphodepleting chemotherapy" to prepare their body (Claims 5, 7).

What it doesn't cover

• —Does not cover treating types of mantle cell lymphoma that are not relapsed or refractory, or that lack the specific Ki-67 or TP53 mutation markers (Claim 1).
• —Does not cover CAR T cell therapies that use T cells from a donor (allogeneic) rather than the patient's own (autologous) cells (Claim 1).
• —Does not cover CAR T cells designed to target cancer markers other than CD19, or those using a different anti-CD19 component than the FMC63 single-chain variable fragment (scFv) (Claim 1).
• —Does not cover CAR T cells prepared without the specific steps of positive enrichment and partial or complete depletion of circulating cancer cells from peripheral blood mononuclear cells (Claim 1).
• —Does not cover CAR T cells that use different intracellular signaling regions than the specified CD28 and CD3-zeta domains (Claim 1).

The clever bit

The novelty lies in precisely defining the patient population (relapsed/refractory MCL with specific genetic markers) and the exact CAR T cell construct and preparation method (autologous, anti-CD19 FMC63 scFv, CD28/CD3-zeta signaling, specific enrichment/depletion) to improve outcomes for these challenging cases.

Why it matters

Mantle cell lymphoma (MCL) is an aggressive blood cancer that is often difficult to treat, especially after initial therapies fail. This patent focuses on a specific, challenging subset of MCL patients, offering a new approach using genetically engineered T cells. Kite Pharma, the assignee, is a major player in the CAR T cell therapy field, having developed one of the first approved CAR T cell treatments. This patent aims to refine and expand the application of this powerful technology for a critical patient population.

Real-world examples

• 1.Yescarta (axicabtagene ciloleucel, developed by Kite Pharma/Gilead Sciences)
• 2.Other CD19-targeted CAR T cell therapies for lymphoma
• 3.Clinical trials for CAR T cell therapies in relapsed/refractory MCL